SynthesisPloS one2014
Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention.
Synthesis in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03923595 (The Puglia HCV Micro-elimination in People With Substance Use Disorders), which is not on this map. Cited by 102 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Puglia HCV Micro-elimination in People With Substance Use Disorders
Who cites it
102 citing papers in PubMed, 8 syntheses or guidelines pooled it.
- Community viral load and hepatitis C virus infection: Community viral load measures to aid public health treatment efforts and program evaluation.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2020Pooled it
- Pooled it
- Hepatitis B/C in the countries of the EU/EEA: a systematic review of the prevalence among at-risk groups.BMC infectious diseases · 2018Pooled it
- High hepatitis C virus prevalence among drug users in Iran: systematic review and meta-analysis of epidemiological evidence (2001-2012).International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2015Pooled it
- Incidence of sexually transmitted hepatitis C virus infection in HIV-positive men who have sex with men.AIDS (London, England) · 2015Pooled it
- Hepatitis C virus (HCV) disease progression in people who inject drugs (PWID): A systematic review and meta-analysis.The International journal on drug policy · 2015Pooled it
- Recommendations for the management of hepatitis C virus infection among people who inject drugs.The International journal on drug policy · 2015Guideline
- A systematic review of Hepatitis C virus treatment uptake among people who inject drugs in the European Region.BMC infectious diseases · 2014Pooled it
- Chronic Hepatitis C Virus Infection and the Proinflammatory Effects of Injection Drug Use.The Journal of infectious diseases · 2016Trial
- Epidemiology of hepatitis C virus infection among people receiving opioid substitution therapy (ECHO): study protocol.BMC infectious diseases · 2015Trial
- Silent mutations in coding regions of Hepatitis C virus affect patterns of HCV RNA structures and attenuate viral replication and pathogenesis.Genome biology · 2025Article
- Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions.Nature reviews. Gastroenterology & hepatology · 2024Review
- Elimination of HCV Infection: Recent Epidemiological Findings, Barriers, and Strategies for the Coming Years.Viruses · 2024Review
- HCV testing and linkage to care for hepatitis C virus infection for marginalized drug user populations attending a harm reduction service in Bologna, Italy.Le infezioni in medicina · 2024Article
- Article
- Hepatitis C Virus-HIV Coinfection in the United States Among People Who Inject Drugs: Data Needed for Ending Dual Epidemics.Public health reports (Washington, D.C. : 1974) · 2023Review
- Real-world hepatitis C treatment outcomes and reinfections among people who inject drugs at a needle and syringe program in Stockholm, Sweden.Harm reduction journal · 2023Article
- Article
- HCV Genotype Distribution Among People Who Inject Drug in Turkey: Findings from Multicenter and Cross-Sectional Study.Substance abuse : research and treatment · 2023Article
- Pilot Outreach Program in Remedis-The Promising Step toward HCV Elimination among People Who Inject Drugs.International journal of environmental research and public health · 2022Article
42 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPeople who inject drugs (PWID) are a key population affected by hepatitis C virus (HCV). Treatment options are improving and may enhance prevention; however access for PWID may be poor. The availability in the literature of information on seven main topic areas (incidence, chronicity, genotypes, HIV co-infection, diagnosis and treatment uptake, and burden of disease) to guide HCV treatment and prevention scale-up for PWID in the 27 countries of the European Union is systematically reviewed. METHODS AND
findingsWe searched MEDLINE, EMBASE and Cochrane Library for publications between 1 January 2000 and 31 December 2012, with a search strategy of general keywords regarding viral hepatitis, substance abuse and geographic scope, as well as topic-specific keywords. Additional articles were found through structured email consultations with a large European expert network. Data availability was highly variable and important limitations existed in comparability and representativeness. Nine of 27 countries had data on HCV incidence among PWID, which was often high (2.7-66/100 person-years, median 13, Interquartile range (IQR) 8.7-28). Most common HCV genotypes were G1 and G3; however, G4 may be increasing, while the proportion of traditionally 'difficult to treat' genotypes (G1+G4) showed large variation (median 53, IQR 43-62). Twelve countries reported on HCV chronicity (median 72, IQR 64-81) and 22 on HIV prevalence in HCV-infected PWID (median 3.9%, IQR 0.2-28). Undiagnosed infection, assessed in five countries, was high (median 49%, IQR 38-64), while of those diagnosed, the proportion entering treatment was low (median 9.5%, IQR 3.5-15). Burden of disease, where assessed, was high and will rise in the next decade.
conclusionKey data on HCV epidemiology, care and disease burden among PWID in Europe are sparse but suggest many undiagnosed infections and poor treatment uptake. Stronger efforts are needed to improve data availability to guide an increase in HCV treatment among PWID.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.